Video Insights
Video Insights
Shilpa Gupta, MDAdvanced Urothelial Carcinoma | July 16, 2024
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
View More
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | July 9, 2024
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
Vishnu MurthyCRPC | July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Vignesh T. Packiam, MDUpper Tract Urothelial Carcinoma | June 26, 2024
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Sandip Prasad, MD, MPhilNon-Muscle Invasive Urothelial Carcinoma | June 26, 2024
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
Rana McKay, MDRenal Cell Carcinoma Diagnostics | June 25, 2024
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Niklas Klümper, MDAdvanced Urothelial Carcinoma | June 21, 2024
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Oliver Sartor, MDRLT | June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Geoffrey Johnson, MD, PhDRLT | June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Michael D. Stifelman, MDLocalized | June 17, 2024
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Pedro Barata, MDCRPC | June 13, 2024
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC.
Ovidio Fernandez Calvo, MDMuscle Invasive Urothelial Carcinoma | June 13, 2024
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Karine Tawagi, MDAdvancements in Oncology | June 13, 2024
Dr. Tawagi provides an update as to when SG or chemotherapy should be preferred for patients who do not respond to EV/pembro.